Alendronate, a popular anti-osteoporotic agent, is effective in GBM treatment as it inhibits farnesyl diphosphate synthase (an enzyme involved in isoprenoid biosynthesis and GSCs’ maintenance) that in turn, reduces embryonic stem-cell features and activation of pathways related to necrosis and development in GBM cells (62). The gene discussed is FDPS; the disease is glioblastoma.